1. PRODUCT OVERVIEW
1.1. MARKET DEFINITION
1.2. SCOPE OF THE MARKET
1.2.1. MARKETS COVERED
1.2.2. YEARS CONSIDERED FOR STUDY
1.2.3. KEY MARKET SEGMENTATIONS
2. RESEARCH METHODOLOGY
2.1. OBJECTIVE OF THE STUDY
2.2. BASELINE METHODOLOGY
2.3. KEY INDUSTRY PARTNERS
2.4. MAJOR ASSOCIATION AND SECONDARY SOURCES
2.5. FORECASTING METHODOLOGY
2.6. DATA TRIANGULATION & VALIDATION
2.7. ASSUMPTIONS AND LIMITATIONS
3. EXECUTIVE SUMMARY
3.1. OVERVIEW OF THE MARKET
3.2. OVERVIEW OF KEY MARKET SEGMENTATIONS
3.3. OVERVIEW OF KEY MARKET PLAYERS
3.4. OVERVIEW OF KEY REGIONS/COUNTRIES
3.5. OVERVIEW OF MARKET DRIVERS, CHALLENGES, TRENDS
4. VOICE OF CUSTOMER
5. JAPAN ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
5.1. MARKET SIZE & FORECAST
5.1.1. BY VALUE
5.2. MARKET SHARE & FORECAST
5.2.1. BY PRODUCT (CHOLINESTERASE INHIBITORS, NMDA RECEPTOR ANTAGONIST, COMBINATION DRUG, PIPELINE DRUGS)
5.2.2. BY END USER (HOSPITAL PHARMACY, RETAIL PHARMACY, E-COMMERCE)
5.2.3. BY REGION
5.2.4. BY COMPANY (2024)
5.3. MARKET MAP
6. HOKKAIDO ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
6.1. MARKET SIZE & FORECAST
6.1.1. BY VALUE
6.2. MARKET SHARE & FORECAST
6.2.1. BY PRODUCT
6.2.2. BY END USER
7. TOHOKU ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
7.1. MARKET SIZE & FORECAST
7.1.1. BY VALUE
7.2. MARKET SHARE & FORECAST
7.2.1. BY PRODUCT
7.2.2. BY END USER
8. KANTO ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
8.1. MARKET SIZE & FORECAST
8.1.1. BY VALUE
8.2. MARKET SHARE & FORECAST
8.2.1. BY PRODUCT
8.2.2. BY END USER
9. CHUBU ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
9.1. MARKET SIZE & FORECAST
9.1.1. BY VALUE
9.2. MARKET SHARE & FORECAST
9.2.1. BY PRODUCT
9.2.2. BY END USER
10. KANSAI ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
10.1. MARKET SIZE & FORECAST
10.1.1. BY VALUE
10.2. MARKET SHARE & FORECAST
10.2.1. BY PRODUCT
10.2.2. BY END USER
11. CHUGOKU ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
11.1. MARKET SIZE & FORECAST
11.1.1. BY VALUE
11.2. MARKET SHARE & FORECAST
11.2.1. BY PRODUCT
11.2.2. BY END USER
12. SHIKOKU ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
12.1. MARKET SIZE & FORECAST
12.1.1. BY VALUE
12.2. MARKET SHARE & FORECAST
12.2.1. BY PRODUCT
12.2.2. BY END USER
13. KYUSHU ALZHEIMER’S THERAPEUTICS MARKET OUTLOOK
13.1. MARKET SIZE & FORECAST
13.1.1. BY VALUE
13.2. MARKET SHARE & FORECAST
13.2.1. BY PRODUCT
13.2.2. BY END USER
14. MARKET DYNAMICS
14.1. DRIVERS
14.2. CHALLENGES
15. MARKET TRENDS & DEVELOPMENTS
15.1. RECENT DEVELOPMENTS
15.2. PRODUCT LAUNCHES
15.3. MERGERS & ACQUISITIONS
16. JAPAN ALZHEIMER’S THERAPEUTICS MARKET: SWOT ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. EISAI CO., LTD.
17.1.1. BUSINESS OVERVIEW
17.1.2. PRODUCT & SERVICE OFFERINGS
17.1.3. RECENT DEVELOPMENTS
17.1.4. FINANCIALS (IF LISTED)
17.1.5. KEY PERSONNEL
17.1.6. SWOT ANALYSIS
17.2. OTSUKA HOLDINGS CO., LTD.
17.3. ASTELLAS PHARMA INC
17.4. MITSUBISHI TANABE PHARMA CORPORATION
17.5. SUMITOMO PHARMA CO., LTD
17.6. TAKEDA PHARMACEUTICAL COMPANY LIMITED
17.7. F. HOFFMANN-LA ROCHE LTD
17.8. NOVARTIS AG
17.9. PFIZER INC.
17.10.H. LUNDBECK A/S
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
著作権 ©2022 無断複写・転載を禁じます
